Literature DB >> 29769182

Clinical Pharmacodynamics: Principles of Drug Response and Alterations in Kidney Disease.

Frieder Keller1, Alexander Hann2.   

Abstract

Pharmacokinetics and pharmacodynamics follow the logic of cause and consequence. Receptor-mediated and reversible effects can be distinguished from direct and irreversible effects. Reversible effects are capacity-limited and saturable whereas irreversible effects are limited only by the number of viable targets. In the case of receptor-mediated and reversible effects a threshold and a ceiling concentration can be defined. Antimicrobial drugs with concentration-dependent action are distinguished from drugs with time-dependent action. Concentration-dependent effects are associated with a high ceiling concentration and the target is the high peak. Time-dependent effects are associated with a high threshold concentration and the target is the high trough. During kidney dysfunction, alterations of drug response are usually attributed to pharmacokinetic but rarely to pharmacodynamic changes. Dose adjustment calculations, therefore, tacitly presume that pharmacodynamic parameters remain unchanged while only pharmacokinetic parameters are altered in kidney failure. Kidney dysfunction influences the pharmacokinetic parameters of at least 50% of all essential drugs. Clinicians usually consider pharmacokinetics when kidney disease is found, but pharmacodynamics is as important. Alterations of pharmacodynamic parameters are conceivable but only rarely reported in kidney failure. Sometimes surprising dosing adjustments are needed when pharmacodynamic concepts are brought into the decision process of which dose to choose. Pharmacokinetics and pharmacodynamics should both be considered when any dosing regimen is determined.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Tacrolimus; chemotherapy; kidney failure; pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 29769182      PMCID: PMC6140566          DOI: 10.2215/CJN.10960917

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  50 in total

1.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

2.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

3.  Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.

Authors:  Peter A McCullough; Timothy Ball; Katy Mathews Cox; Manish D Assar
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-25       Impact factor: 8.237

4.  Cyclophosphamide therapy of severe systemic necrotizing vasculitis.

Authors:  A S Fauci; P Katz; B F Haynes; S M Wolff
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

5.  Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Authors:  Fabien Le Bras; Marie Sebert; Charikleia Kelaidi; Thierry Lamy; François Dreyfus; Jacques Delaunay; Anne Banos; Michel Blanc; Norbert Vey; Aline Schmidt; Sorin Visanica; Virginie Eclache; Pascal Turlure; Odile Beyne-Rauzy; Agnès Guerci; Alain Delmer; Stéphane de Botton; Delphine Rea; Pierre Fenaux; Lionel Adès
Journal:  Leuk Res       Date:  2011-06-28       Impact factor: 3.156

Review 6.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06

7.  Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.

Authors:  Hala Yamout; Vlado Perkovic; Melanie Davies; Vincent Woo; Dick de Zeeuw; Cristiana Mayer; Ujjwala Vijapurkar; Irina Kline; Keith Usiskin; Gary Meininger; George Bakris
Journal:  Am J Nephrol       Date:  2014-07-17       Impact factor: 3.754

8.  Cisplatin induces cell cycle arrest and senescence via upregulating P53 and P21 expression in HepG2 cells.

Authors:  Kai Qu; Ting Lin; Jichao Wei; Fandi Meng; Zhixin Wang; Zichao Huang; Yong Wan; Sidong Song; Sinan Liu; Hulin Chang; Yafeng Dong; Chang Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2013-09

9.  How to calculate the dose of chemotherapy.

Authors:  Howard Gurney
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.

Authors:  Andreas Carus; Howard Gurney; Val Gebski; Paul Harnett; Rina Hui; Richard Kefford; Nicholas Wilcken; Morten Ladekarl; Hans von der Maase; Frede Donskov
Journal:  J Transl Med       Date:  2013-08-15       Impact factor: 5.531

View more
  3 in total

1.  Clinical Pharmacology in Diuretic Use.

Authors:  David H Ellison
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-01       Impact factor: 8.237

2.  Adverse Drug Effects in Patients with CKD: Primum Non Nocere.

Authors:  Mark A Perazella; Thomas D Nolin
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

3.  Management of Drug-Drug Interactions among Critically Ill Patients with Chronic Kidney Disease: Impact of Clinical Pharmacist's Interventions.

Authors:  Mina Aghili; Meera Neelathahalli Kasturirangan
Journal:  Indian J Crit Care Med       Date:  2021-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.